Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 426 to 450 of 2428

TitleReference numberPublishedLast updated
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasiaMIB306
Colorectal cancer prevention: colonoscopic surveillance in adults with ulcerative colitis, Crohn's disease or adenomasCG118
Melphalan for haematological diseases before allogeneic haematopoietic stem cell transplant (terminated appraisal)TA822
Dexamethasone intravitreal implant for treating diabetic macular oedemaTA824
Self-harm: assessment, management and preventing recurrenceNG225
Self‑harmQS34
Brolucizumab for treating diabetic macular oedemaTA820
Faecal microbiota transplant for recurrent Clostridioides difficile infectionMTG71
iFuse for treating chronic sacroiliac joint painMTG39
Contrast-enhanced spectral mammography for breast cancerMIB304
Differential target multiplexed spinal cord stimulation for chronic lower back and leg painMIB305
Avalglucosidase alfa for treating Pompe diseaseTA821
Focal resurfacing implants to treat articular cartilage damage in the kneeIPG734
Transcutaneous electrical neuromuscular stimulation for urinary incontinenceIPG735
Superficial venous arterialisation for chronic limb threatening ischaemiaIPG736
Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapiesTA819
Nivolumab with ipilimumab for untreated unresectable malignant pleural mesotheliomaTA818
Cefiderocol for treating severe drug-resistant gram-negative bacterial infectionsHTE2
Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infectionsHTE1
Type 1 diabetes in adults: diagnosis and managementNG17
Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDsTA815
Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancerTA816
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrenceTA817
SecurAcath for securing percutaneous cathetersMTG34
Stockholm3 for prostate cancer screeningMIB303

Results per page

  1. 10
  2. 25
  3. 50
  4. All